Table 2. Distribution of participants with ivermectin prophylaxis.
COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
| Ivermectin two-dose prophylaxis | |||
| Variables | Yes | No | p-value |
| Age (years) | <0.001 | ||
| <30 | 1115 (50.7) | 772 (57.9) | |
| 30-39 | 705 (32.1) | 434 (32.6) | |
| 40-49 | 262 (11.9) | 96 (7.2) | |
| ≥50 | 117 (5.3) | 31 (2.3) | |
| Gender | <0.001 | ||
| Male | 1622 (67.9) | 767 (32.1) | |
| Female | 577 (50.5) | 566 (49.5) | |
| Profession | 0.236 | ||
| Staff involved in COVID-19 patient care | 1582 (71.9) | 985 (73.9) | |
| Administrative staff | 306 (13.9) | 186 (13.9) | |
| Students | 311 (14.2) | 162 (12.2) | |
| Symptoms suggestive of SARS-CoV-2 infection during follow-up | <0.001 | ||
| Positive | 131 (6.0) | 200 (15.0) | <0.001 |
| Negative | 2068 (94.0) | 1133 (85.0) | |